Cantor Fitzgerald Estimates FDMT FY2025 Earnings

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) – Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of 4D Molecular Therapeutics in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer forecasts that the company will earn ($3.46) per share for the year. The consensus estimate for 4D Molecular Therapeutics’ current full-year earnings is ($2.84) per share.

A number of other equities research analysts also recently issued reports on FDMT. Morgan Stanley reduced their price target on shares of 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating on the stock in a research note on Monday, January 13th. Leerink Partners decreased their price target on 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating on the stock in a research note on Monday, January 13th. HC Wainwright restated a “buy” rating and set a $36.00 price target on shares of 4D Molecular Therapeutics in a research report on Monday, January 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Saturday. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $39.00 target price on shares of 4D Molecular Therapeutics in a research report on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $38.56.

4D Molecular Therapeutics Trading Up 2.0 %

Shares of FDMT opened at $4.67 on Wednesday. The firm has a market cap of $215.89 million, a P/E ratio of -1.64 and a beta of 2.81. The company’s 50-day moving average price is $6.52 and its 200 day moving average price is $11.19. 4D Molecular Therapeutics has a 12-month low of $4.48 and a 12-month high of $36.25.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Algert Global LLC increased its stake in 4D Molecular Therapeutics by 20.6% in the second quarter. Algert Global LLC now owns 16,588 shares of the company’s stock valued at $348,000 after purchasing an additional 2,828 shares during the last quarter. nVerses Capital LLC acquired a new stake in 4D Molecular Therapeutics during the 3rd quarter worth $40,000. The Manufacturers Life Insurance Company lifted its position in 4D Molecular Therapeutics by 25.5% in the second quarter. The Manufacturers Life Insurance Company now owns 18,975 shares of the company’s stock valued at $398,000 after acquiring an additional 3,850 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in 4D Molecular Therapeutics by 64.6% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,995 shares of the company’s stock valued at $108,000 after acquiring an additional 3,922 shares in the last quarter. Finally, Values First Advisors Inc. purchased a new position in shares of 4D Molecular Therapeutics during the third quarter worth about $57,000. Hedge funds and other institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.